Therapeutics News and Research

RSS

COVID-19 during pregnancy can cause placental inflammation and impaired immunity

A new study conducted by a team of researchers at Johns Hopkins University, USA, has observed how pregnant women infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) show stunted antiviral immune responses.

18 Nov 2020

SARS-CoV-2 causes a unique cytokine storm, study finds

A new study published on the preprint server medRxiv* in November 2020 reports some of the unique elements of COVID-19-induced CRS and how understanding these distinctive characteristics of the disease could help in formulating specific interventions and therapies.

18 Nov 2020

A game-changing collaboration to accelerate drug development for Alzheimer's disease

The Critical Path Institute's (C-Path) Critical Path for Alzheimer's Disease (CPAD) Consortium today announced its participation as a Partner with the Alzheimer's Disease Data Initiative (ADDI), a 501(c)(3) medical research organization which launched today.

18 Nov 2020

Natural products and herbal medicines show promise in fight against COVID-19

Researchers in China and the United States have called for more research into the potential prophylactic effects of natural products and herbal medicines on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and subsequent coronavirus disease 2019 (COVID-19).

17 Nov 2020

Researchers report encouraging results from in vitro combination therapy against COVID-19

Researchers at Karolinska Institutet in Sweden report promising results from an in vitro combination therapy against COVID-19.

17 Nov 2020

Study shows favorable impact of medication on cardiac structure and function

For the first time, medication has impacted heart muscle thickness and function for patients with the most common inherited heart condition, rather than simply addressing their symptoms.

17 Nov 2020

Antiviral immune response is suppressed in COVID-19 patients compared to flu patients

Rather than life-threatening hyperinflammation, most adults with moderate-to-severe COVID-19 have a suppressed viral immune response when compared to adults with another viral respiratory infection, influenza. St. Jude Children's Research Hospital and Washington University School of Medicine in St. Louis led research that suggests most COVID-19 patients are not candidates for treatment with steroids such as dexamethasone.

16 Nov 2020

CEAT project for improving ovarian cancer diagnosis, treatment shows promise

Porvair Sciences reports, due to promising results, it has agreed with its collaborative partners to make additional investment in the CEAT project which aims to dramatically improve the diagnosis and treatment of ovarian cancer.

From Porvair Sciences Limited 16 Nov 2020

Global health leaders discuss the urgent funding needs of ACT Accelerator

Heads of state, global health leaders, scientists, and the private sector have come together at the Paris Peace Forum this week to discuss how to meet the urgent funding needs of the ACT Accelerator.

16 Nov 2020

PARP inhibitor, stenoparib inhibits pre- and post-entry processes of SARS-CoV-2 in vitro

A team of researchers from the Northern Arizona University evaluated a new PARP inhibitor, stenoparib, which has recently advanced to Stage II of clinical trials to treat ovarian cancer. Their study, an initial report on in vitro stenoparib activity against human coronaviruses such as SARS-CoV-2, has been published on the preprint server bioRxiv*.

15 Nov 2020

Promising new compounds to potentially treat novel coronaviruses identified

Researchers at the University of Maryland School of Medicine and School of Pharmacy have discovered new drug compounds to potentially treat the novel coronavirus that causes COVID-19.

15 Nov 2020

Ovarian cancer project shows promise

Porvair Sciences reports, due to promising results, it has agreed with its collaborative partners to make additional investment in the CEAT project** which aims to dramatically improve the diagnosis and treatment of ovarian cancer.

From Chromatrap® - Porvair Sciences Ltd 13 Nov 2020

Study helps quantify racial and ethnic disparities in pediatric diabetes treatment

Type 1 diabetes (T1D) is the third most common pediatric chronic disease in the United States, and the risk of the disease has risen sharply in non-Hispanic Black (NHB) children in the last 20 years, data show.

12 Nov 2020

Researchers identify acrylamides that inhibit SARS-CoV-2 main protease

A new study in the preprint server bioRxiv published in November 2020 describes the discovery of acrylamide fragments that can effectively disable key enzymes in both the hand, foot and mouth virus and SARS-CoV-2 virus.

11 Nov 2020

MD Anderson presents positive clinical data from combination cancer therapies at SITC 2020

Promising clinical results with combination treatments for patients with melanoma and lung cancer highlight immunotherapy advances being presented by researchers from The University of Texas MD Anderson Cancer Center at The Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting & Pre-Conference Programs.

11 Nov 2020

IU researcher awarded NCI grant to develop a drug for making radiation therapy more effective

An Indiana University Melvin and Bren Simon Comprehensive Cancer Center researcher has been awarded a five-year, $2.9 million grant from the National Cancer Institute to develop a drug that could make radiation therapy far more effective.

11 Nov 2020

Gene signature may help develop new therapies against advanced prostate cancer

Researchers have identified a genetic signature in localized prostate cancer that can predict whether the cancer is likely to spread, or metastasize, early in the course of the disease and whether it will respond to anti-androgen therapy, a common treatment for advanced disease.

11 Nov 2020

SARS-CoV-2 RNA genome structure reveals potential targets for development of drugs

The SARS-CoV-2 coronavirus RNA genome structure was studied in detail by researchers from the University of Groningen, the International Institute of Molecular and Cell Biology in Warsaw, and Leiden University.

10 Nov 2020

Endothelial cells resistant to SARS-CoV-2 infection

A team of scientists from Imperial College London has conducted a series of in vitro studies to investigate the susceptibility of endothelial cells to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the causative pathogen of coronavirus disease 2019 (COVID-19).

10 Nov 2020

Novel 3D-printed scaffold loaded with chemotherapy drug could reduce breast cancer recurrence

The recurrence of cancer after surgery is a major concern for patients. New findings from a QUT study have shown the potential for a novel 3D-printed porous scaffold which is loaded with a common chemotherapy drug that can reduce breast cancer recurrence in an experimental setting.

10 Nov 2020

Therapeutics News and Research

COVID-19 during pregnancy can cause placental inflammation and impaired immunity

SARS-CoV-2 causes a unique cytokine storm, study finds

A game-changing collaboration to accelerate drug development for Alzheimer's disease

Natural products and herbal medicines show promise in fight against COVID-19

Researchers report encouraging results from in vitro combination therapy against COVID-19

Study shows favorable impact of medication on cardiac structure and function

Antiviral immune response is suppressed in COVID-19 patients compared to flu patients

CEAT project for improving ovarian cancer diagnosis, treatment shows promise

Global health leaders discuss the urgent funding needs of ACT Accelerator

PARP inhibitor, stenoparib inhibits pre- and post-entry processes of SARS-CoV-2 in vitro

Promising new compounds to potentially treat novel coronaviruses identified

Ovarian cancer project shows promise

Study helps quantify racial and ethnic disparities in pediatric diabetes treatment

Researchers identify acrylamides that inhibit SARS-CoV-2 main protease

MD Anderson presents positive clinical data from combination cancer therapies at SITC 2020

IU researcher awarded NCI grant to develop a drug for making radiation therapy more effective

Gene signature may help develop new therapies against advanced prostate cancer

SARS-CoV-2 RNA genome structure reveals potential targets for development of drugs

Endothelial cells resistant to SARS-CoV-2 infection

Novel 3D-printed scaffold loaded with chemotherapy drug could reduce breast cancer recurrence

Industry Focus eBook - Cell biology (5th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News